| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BPMC Stock Overview
Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe.
Blueprint Medicines Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$68.91 |
| 52 Week High | US$117.86 |
| 52 Week Low | US$68.80 |
| Beta | 0.72 |
| 1 Month Change | -37.90% |
| 3 Month Change | -32.78% |
| 1 Year Change | -32.02% |
| 3 Year Change | -0.59% |
| 5 Year Change | 98.93% |
| Change since IPO | 265.18% |
Recent News & Updates
Shareholder Returns
| BPMC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -11.7% | -7.4% | -6.1% |
| 1Y | -32.0% | -21.7% | 4.2% |
Return vs Industry: BPMC underperformed the US Biotechs industry which returned -22% over the past year.
Return vs Market: BPMC underperformed the US Market which returned 4.2% over the past year.
Price Volatility
| BPMC volatility | |
|---|---|
| BPMC Average Weekly Movement | 7.2% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.4% |
Stable Share Price: BPMC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: BPMC's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 476 | Jeff Albers | https://www.blueprintmedicines.com |
Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and hematologic disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945, a selective and potent investigational inhibitors of double-mutant EGFR harboring, which are in preclinical stage for patient with EGFR-driven NSCLC.
Blueprint Medicines Fundamentals Summary
| BPMC fundamental statistics | |
|---|---|
| Market Cap | US$4.05b |
| Earnings (TTM) | -US$411.07m |
| Revenue (TTM) | US$107.17m |
37.8x
P/S Ratio-9.9x
P/E RatioIs BPMC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BPMC income statement (TTM) | |
|---|---|
| Revenue | US$107.17m |
| Cost of Revenue | US$335.34m |
| Gross Profit | -US$228.18m |
| Expenses | US$182.89m |
| Earnings | -US$411.07m |
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | -6.99 |
| Gross Margin | -212.92% |
| Net Profit Margin | -383.58% |
| Debt/Equity Ratio | 0% |
How did BPMC perform over the long term?
See historical performance and comparisonValuation
Is Blueprint Medicines undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BPMC ($68.91) is trading below our estimate of fair value ($360.44)
Significantly Below Fair Value: BPMC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BPMC is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: BPMC is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BPMC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BPMC is overvalued based on its PB Ratio (3.3x) compared to the US Biotechs industry average (1.9x).
Future Growth
How is Blueprint Medicines forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
54.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BPMC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: BPMC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: BPMC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: BPMC's revenue (40.7% per year) is forecast to grow faster than the US market (9.1% per year).
High Growth Revenue: BPMC's revenue (40.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BPMC is forecast to be unprofitable in 3 years.
Past Performance
How has Blueprint Medicines performed over the past 5 years?
13.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BPMC is currently unprofitable.
Growing Profit Margin: BPMC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BPMC is unprofitable, but has reduced losses over the past 5 years at a rate of 13.1% per year.
Accelerating Growth: Unable to compare BPMC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BPMC is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).
Return on Equity
High ROE: BPMC has a negative Return on Equity (-32.96%), as it is currently unprofitable.
Financial Health
How is Blueprint Medicines's financial position?
Financial Position Analysis
Short Term Liabilities: BPMC's short term assets ($771.8M) exceed its short term liabilities ($119.7M).
Long Term Liabilities: BPMC's short term assets ($771.8M) exceed its long term liabilities ($110.5M).
Debt to Equity History and Analysis
Debt Level: BPMC is debt free.
Reducing Debt: BPMC has no debt compared to 5 years ago when its debt to equity ratio was 4.9%.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BPMC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if BPMC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Dividend
What is Blueprint Medicines's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate BPMC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate BPMC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if BPMC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if BPMC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of BPMC's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.8yrs
Average management tenure
CEO
Jeff Albers (50 yo)
7.5yrs
Tenure
US$6,344,667
Compensation
Mr. Jeffrey W. Albers, also known as Jeff, J.D., MBA, serves as Chairman of the Board at Blueprint Medicines Corporation since June 2021. He has been Independent Director of Kymera Therapeutics, Inc. (Prev...
CEO Compensation Analysis
Compensation vs Market: Jeff's total compensation ($USD6.34M) is about average for companies of similar size in the US market ($USD5.29M).
Compensation vs Earnings: Jeff's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: BPMC's management team is considered experienced (4.8 years average tenure).
Board Members
Experienced Board: BPMC's board of directors are considered experienced (7.5 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.6%.
Top Shareholders
Company Information
Blueprint Medicines Corporation's employee growth, exchange listings and data sources
Key Information
- Name: Blueprint Medicines Corporation
- Ticker: BPMC
- Exchange: NasdaqGS
- Founded: 2008
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$4.055b
- Shares outstanding: 58.84m
- Website: https://www.blueprintmedicines.com
Number of Employees
Location
- Blueprint Medicines Corporation
- 45 Sidney Street
- Cambridge
- Massachusetts
- 02139-4133
- United States
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/01/23 23:04 |
| End of Day Share Price | 2022/01/21 00:00 |
| Earnings | 2021/09/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.